Squalene synthase inhibitor lapaquistat acetate: Could anything be better than statins?

Circulation

Volumn 123, Issue 18, 2011, Pages 1925-1928

  Liao, James K ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

cholesterol; hepatoxicity; isoprenoids; mevalonate; myopathy; squalene

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; BILE ACID SEQUESTRANT; CREATINE KINASE; DOLICHOL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; EZETIMIBE; FARNESOL; FARNESYL DIPHOSPHATE; GERANYLGERANIOL; GERANYLGERANYL PYROPHOSPHATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOPENTENYL DIPHOSPHATE; ISOPRENOID; LAPAQUISTAT ACETATE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVALONIC ACID; PLASMINOGEN ACTIVATOR INHIBITOR; PYROPHOSPHATE; RAS PROTEIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; ROSUVASTATIN; SQUALENE SYNTHASE INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL; UBIDECARENONE; UBIQUINONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE CORONARY SYNDROME; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CORONARY ARTERY DISEASE; CREATINE KINASE BLOOD LEVEL; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; FAMILIAL HYPERCHOLESTEROLEMIA; GLYCOSYLATION; HETEROZYGOSITY; HIGH RISK PATIENT; HOMOZYGOSITY; HUMAN; HYPERCHOLESTEROLEMIA; LIVER TOXICITY; MITOCHONDRIAL RESPIRATION; MONOTHERAPY; MYOPATHY; MYOTOXICITY; NEGATIVE FEEDBACK; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLEIOTROPY; PRIMARY PREVENTION; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RECEPTOR UPREGULATION; REVIEW; RHABDOMYOLYSIS; RISK BENEFIT ANALYSIS; RISK REDUCTION; SECONDARY PREVENTION; TOXICITY;

ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; FARNESYL-DIPHOSPHATE FARNESYLTRANSFERASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; OXAZEPINES; PIPERIDINES;

EID: 79955765053     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.111.028571     Document Type: Review

References (19)

1. Sytkowski PA, Kannel WB, D'Agostino RB. Changes in risk factors and the decline in mortality from cardiovascular disease. The Framingham Heart Study. N Engl J Med. 1990;322:1635-1641. (Pubitemid 20171587)
2. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ. Implications of recent clinical trials for the national cholesterol education program adult treatment panel iii guidelines. Circulation. 2004;110:227-239. (Pubitemid 38924592)
3. Illingworth DR. Management of hypercholesterolemia. Med Clin North Am. 2000;84:23-42. (Pubitemid 30068890)
4. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-1504. (Pubitemid 38477774)
5. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-1435. (Pubitemid 40471450)
6. Jacobson TA, Griffiths GG, Varas C, Gause D, Sung JC, Ballantyne CM. Impact of evidence-based "clinical judgment" on the number of American adults requiring lipid-lowering therapy based on updated NHANES III data. National Health and Nutrition Examination Survey. Arch Intern Med. 2000;160:1361-1369. (Pubitemid 30252785)
7. Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, Cain VA, Blasetto JW. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* trial). Am J Cardiol. 2003;92:152-160. (Pubitemid 36835963)
8. Brewer HB Jr. Benefit-risk assessment of rosuvastatin 10 to 40 milligrams. Am J Cardiol. 2003;92:23K-29K.
9. Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000;160:459-467. (Pubitemid 30112269)
10. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005;45:89-118. (Pubitemid 40261799)
11. Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, Visseren FL, Sijbrands EJ, Trip MD, Stein EA, Gaudet D, Duivenvoorden R, Veltri EP, Marais AD, De Groot E. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008; 358:1431-1443. (Pubitemid 351482735)
12. Califf RM, Lokhnygina Y, Cannon CP, Stepanavage ME, McCabe CH, Musliner TA, Pasternak RC, Blazing MA, Giugliano RP, Harrington RA, Braunwald E. An update on the improved reduction of outcomes: Vytorin efficacy international trial (IMPROVE-IT) design. Am Heart J. 2010;159: 705-709.
13. Flint OP, Masters BA, Gregg RE, Durham SK. Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro. Toxicol Appl Pharmacol. 1997;145:91-98. (Pubitemid 27294774)
14. Nishimoto T, Ishikawa E, Anayama H, Hamajyo H, Nagai H, Hirakata M, Tozawa R. Protective effects of a squalene synthase inhibitor, lapaquistat acetate (TAK-475), on statin-induced myotoxicity in guinea pigs. Toxicol Appl Pharmacol. 2007;223:39-45. (Pubitemid 47211267)
15. Stein EA, Bays H, O'Brien D, Pedicano J, Piper E, Spezzi A. Lapaquistat acetate: development of a squalene synthase inhibitor for the treatment of hypercholesterolemia. Circulation. 2011;123:1974-1985.
16. Reuben A. Hy's law. Hepatology. 2004;39:574-578.
17. Charlton-Menys V, Durrington PN. Human cholesterol metabolism and therapeutic molecules. Exp Physiol. 2008;93:27-42. (Pubitemid 350293976)
18. Clofibrate and niacin in coronary heart disease. JAMA. 1975;231: 360-381.
19. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans affairs highdensity lipoprotein cholesterol intervention trial study group. N Engl J Med. 1999;341:410-418. (Pubitemid 29362514)